Intellia Therapeutics (NTLA) EBIT (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly EBIT of -$100.5 million for Q1 2026, up 16.78% year-over-year from -$86.1 million in Q1 2025, and down 1.85% quarter-over-quarter from -$98.7 million in Q4 2025.
Intellia Therapeutics (NTLA) EBIT (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported EBIT for 12 consecutive years, with -$100.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 16.78% year-over-year to -$100.5 million; the TTM figure through Mar 2026 stood at -$420.7 million (up 22.24% YoY), while the FY2025 annual figure was -$441.0 million, up 17.46% from the prior year.
- EBIT eased to -$100.5 million in Q1 2026 per NTLA's latest filing, from -$98.7 million in the prior quarter.
- Across five years, EBIT topped out at -$98.3 million in Q2 2022 and bottomed at -$144.8 million in Q3 2024.
- Historically, EBIT has averaged -$120.5 million across 5 years, with a median of -$114.0 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT plunged 210.71% — and 2025, when it advanced 27.66%.
- Intellia Therapeutics' EBIT stood at -$110.1 million in 2022, then fell by 27.07% to -$139.9 million in 2023, then increased by 2.46% to -$136.4 million in 2024, then increased by 27.66% to -$98.7 million in 2025, then decreased by 1.85% to -$100.5 million in 2026.
- Business Quant data shows NTLA's EBIT at -$100.5 million in Q1 2026, -$98.7 million in Q4 2025, and -$111.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -112.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -112.76 Mn |
| Mar 31, 2026 | -100.53 Mn |
| Dec 31, 2025 | -98.71 Mn |
| Sep 30, 2025 | -111.48 Mn |
| Jun 30, 2025 | -110.00 Mn |
| Mar 31, 2025 | -120.81 Mn |
| Dec 31, 2024 | -136.45 Mn |
| Sep 30, 2024 | -144.77 Mn |
| Jun 30, 2024 | -139.04 Mn |
| Mar 31, 2024 | -114.00 Mn |
| Dec 31, 2023 | -139.89 Mn |
| Sep 30, 2023 | -131.11 Mn |
| Jun 30, 2023 | -132.33 Mn |
| Mar 31, 2023 | -111.96 Mn |
| Dec 31, 2022 | -110.09 Mn |
| Sep 30, 2022 | -105.53 Mn |
| Jun 30, 2022 | -98.30 Mn |
| Mar 31, 2022 | -144.25 Mn |
| Dec 31, 2021 | -80.42 Mn |
| Sep 30, 2021 | -71.99 Mn |